secwatch.observer — SEC 8-K summary
======================================

Issuer:     Chemomab Therapeutics Ltd. (CMMB)
CIK:        0001534248
Form:       8-K
Filed at:   2021-07-22T23:59:59+00:00
Accession:  0001178913-21-002338
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Chemomab Therapeutics Shareholders Approve Compensation, CEO Terms, Share Plan, and Auditor at 2021 Meeting
--------------------------------------------------------------------------------

- Proposal 1: Compensation Policy approved with 103,259,980 votes for (99.5%), meeting Israeli Companies Law requirements for non-controlling shareholders.
- Proposal 2: Amendment to CEO Dr. Adi Mor's engagement terms approved with 103,495,100 votes for (99.7%), satisfying requisite majority.
- Proposal 3: Share incentive plan increase by 540,000 ADSs (10,800,000 ordinary shares) approved with 103,184,280 votes for.
- Proposal 4: Reappointment of Somekh Chaikin (KPMG) as independent auditors approved with 103,862,300 votes for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534248/000117891321002338/0001178913-21-002338-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534248/000117891321002338/zk2126316.htm
  HTML page:      https://secwatch.observer/filing/0001178913-21-002338

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer